Tumors: Molecular origin of the resistance to medical treatment. Pharmacogenetics: correlations between SNPs and proliferation/aggressiveness/drug sensitivity/prognosis of pituitary adenomas. Pituitary adenomas and metabolic/cardiovascular co-morbidities. Development of diagnostic markers in patients with pituitary adenomas. Genetic/Molecular pathogenesis of sellar tumors. Pre-clinical and clinical trials of novel drugs for pituitary tumors, such as Cushing disease or acromegaly.

Development and functional defects: Genetic and molecular origin of isolated (eg, Central Hypothyroidism or Hypogonadism) or Combined Pituitary Hormone Deficiencies (CPHDs) and of Kallmann Syndrome. Biobank of patients with such defects. Clinical and molecular studies in growth and pubertal retardation. Development of predictive tools for genetic counseling. Leadership of NICe (Italian Network on Central Hypogonadism) and participation to a specific “COST action” funded by the EC (BM1105). Clinical studies in the syndrome of inappropriate ADH secretion. Studies on the prevalence of pituitary defects and on the efficacy and safety of rhGH therapy in particular patients (craniopharyngiomas, non-functioning pituitary adenomas, head traumas, stroke, thalassemia major or meningitis).

Premature Ovarian Failure (POF): Genetic origin of POF. Development of novel tools for the prediction of POF risk. Development of novel protocols for the management of POF patients. Fundamental research on ovarian folliculogenesis in mono- or poly-ovulating species.